Synerkine Pharma secures EUR 12.1 million to accelerate novel pain therapeutics towards clinical proof-of-concept

Written By Mario Brkulj

Synerkine Pharma, a Dutch biopharmaceutical company creating innovative pain solutions, today announced an extension of its Series A financing led by Flerie with support from new investors, InnovationQuarter Capital and Utrecht Health Seed Fund, and existing investor Thuja Capital. The equity financing is accompanied by a matching innovation credit from Rijksdienst voor Ondernemend (RVO) Nederland - the Netherlands Enterprise Agency. The total new proceeds of EUR 12.1 million will be used to accelerate the development of Synerkine Pharma’s lead asset SK-01, a therapeutically active cytokine fusion protein, into clinical studies in complex regional pain syndrome (CRPS), a severe chronic pain indication. LEARN MORE

Mario Brkulj
Previous

Synerkine Pharma appoints Industry Veteran Anders Ekblom to its Board of Directors
Next

Synerkine adds New members to advisory board